Published Studies Related to Calcijex (Calcitriol)
Oral Calcitriol for Reduction of Proteinuria in Patients With IgA Nephropathy: A Randomized Controlled Trial. [2011.10.21]
BACKGROUND: Vitamin D has shown efficacy in the reduction of proteinuria in patients with chronic kidney disease. This study aimed to determine the effect of calcitriol on urinary protein excretion in patients with immunoglobulin A (IgA) nephropathy... CONCLUSIONS: The addition of calcitriol to a renin-angiotensin system inhibitor resulted in a safe decrease in proteinuria in patients with IgA nephropathy. Copyright (c) 2011 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. [2011.06.01]
PURPOSE: To compare the efficacy and safety of docetaxel plus high-dose calcitriol (DN-101) to docetaxel plus prednisone in an open-label phase III trial... CONCLUSION: ASCENT treatment was associated with shorter survival than the control. This difference might be due to either weekly docetaxel dosing, which, in a prior study, showed a trend toward inferior survival compared with an every-3-weeks regimen, or DN-101 therapy.
The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. [2011.05]
BACKGROUND: Lanthanum carbonate and sevelamer carbonate are non-calcium-based phosphate binders used to manage hyperphosphataemia in patients with chronic kidney disease (CKD). Patients with CKD may require intravenous or oral active vitamin D. We investigated the effects of lanthanum carbonate and sevelamer carbonate on the bioavailability of oral calcitriol... CONCLUSIONS: Sevelamer carbonate significantly reduces serum concentrations of exogenous calcitriol when administered concomitantly with oral calcitriol, whereas lanthanum carbonate has no significant effect. This should be considered when treating CKD patients who require phosphate binders and oral vitamin D.
Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients. [2011.03]
AIM: Calcitriol and alfacalcidol are used extensively for the treatment of secondary hyperparathyroidism. Unfortunately, there is limited published data comparing the efficacy and tolerability of both active vitamin D sterols. This study was undertaken to determine whether calcitriol provides a therapeutic advantage to alfacalcidol... CONCLUSION: Alfacalcidol can be used to control secondary hyperparathyroidism at doses of 1.5-2.0 times that of calcitriol. The two drugs are equally efficacious and lead to similar changes in calcium and phosphorus. (c) 2011 The Authors. Nephrology (c) 2011 Asian Pacific Society of Nephrology.
Response of plasma bone markers to a single intramuscular administration of calcitriol in dairy cows. [2011.02]
To elucidate the effects of an exogenous calcitriol (1,25-dihydroxyvitamin D(3)) on plasma bone markers, the formation item osteocalcin (OC), undercarboxylated OC (ucOC) and bone-specific alkaline phosphatase (BALP), and the resorption parameter tartrate-resistant acid phosphatase isoform 5b (TRAP5b) and hydroxyproline (HYP) were measured in conjunction with plasma calcitriol and calcium (Ca) concentrations in dairy cows receiving calcitriol or its vehicle according to a 2x2 crossover design...
Clinical Trials Related to Calcijex (Calcitriol)
Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004 [Active, not recruiting]
Phase I/II Calcitriol in Lung Cancer [Recruiting]
According to the Cancer Atlas, lung cancer remains the major cancer among the 10. 9 million
new cases of cancer diagnosed annually worldwide. The mortality from lung cancer is greater
than the combined mortality for breast, colon and prostate cancer combined. Most patients
with metastatic non-small-cell lung cancer (NSCLC) are treated with platinum-based
chemotherapy regimens. The drug combination of cisplatin and docetaxel is one of the
commonly used regimens in metastatic NSCLC. Although both drugs are powerful disruptors of
cell growth, positive therapeutic response rates to this therapy remain low for NSCLC
patients, from 25% to 30%. While adding new biologics such as bevacizumab to the current
treatment standard can improve treatment response, median survival for advanced NSCLC
patients receiving this type of treatment remains low at under 12 months. Research studies
have demonstrated that Vitamin D, and it's signaling pathways are important biological
targets in cancer therapeutics. In vitro and in vivo calcitriol (1, 25
dihydroxycholcalciferol) is antiproliferative and potentiates the antitumor effects of
cytotoxic agents (e. g. taxanes, platinum analogues). We have shown that administration of
high doses of calcitriol and cisplatin is feasible and associated with complete tumor
regressions in dogs with spontaneous cancers. Calcitriol has also shown to be synergistic
with docetaxel both in preclinical as well as in a recent phase II clinical trial in
prostate cancer. Based on these results and other supporting data from studies indicating
that calcitriol functions as a potent and well tolerated anti-tumor agent when used in
combination with drugs likes cisplatin and docetaxel, we hypothesize that introducing
calcitriol into treatment regimes for NSCLC patients has the potential to demonstrably
improve treatment response for these patients. The overall goals for conducting this phase
I/II clinical study will be (1) to determine the maximum tolerated dose (MTD) and dose
limiting toxicities (DLT) of calcitriol in combination with cisplatin/docetaxel in patients
with advanced NSCLC, (2) to assess the response rates of patients with advanced NSCLC to the
combination of calcitriol with cisplatin/docetaxel, (3) to evaluate the pharmacokinetics
(PK) of administering calcitriol intravenously at the MTD, and (4) to evaluate correlations
between calcitriol PK and changes on specific coding regions of the gene associated with
Study of High-Dose Pulse Administration DN-101 (Calcitriol) in Patients With Myelodysplastic Syndrome (MDS) [Active, not recruiting]
The purpose of this study is to determine the safety and efficacy of DN-101 (calcitriol) in
patients with myelodysplastic syndrome who are dependent on repeat blood transfusions.
Vitamin D and Coronary Calcification Study [Recruiting]
Patients with chronic kidney disease (CKD) have a higher mortality rate than the general
population, with cardiovascular disease (CVD) accounting for approximately 50% of deaths.
Vascular calcification is a common finding in patients with CKD. Furthermore, patients with
CKD develop secondary hyperparathyroidism, partly because of a decrease of calcitriol
synthesis on the kidney. Treatment of secondary hyperparathyroidism includes use of
activated vitamin D including calcitriol and paricalcitol. Recent evidence in dialysis
patients suggest an improved survival in patients using paricalcitol compared to calcitriol.
Studies in uremic rats suggests that there are differential effects of calcitriol and
paricalcitol in expression of markers of soft-tissue calcification independent of
calcium-phosphorus product. Calcitriol increased calcification of vascular smooth muscle
cells cultured in calcification media. There was also significant increase in pulse pressure
in animals treated with calcitriol.
The investigators hypothesize that these different forms of vitamin D may have differential
effects in vascular calcification progression in CKD patients.
Calcitriol, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery [Recruiting]
RATIONALE: Drugs used in chemotherapy, such as cisplatin and gemcitabine hydrochloride, work
in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. Calcitriol may stop the growth of tumor cells by blocking blood
flow to the tumor. Calcitriol may also help cisplatin and gemcitabine hydrochloride kill
more tumor cells by making them more sensitive to the drug. PURPOSE: This phase I trial
is studying the side effects and best dose of calcitriol when given together with cisplatin
and gemcitabine hydrochloride in treating patients with advanced solid tumors that cannot be
removed by surgery.